Stephen P Fortmann
Overview
Explore the profile of Stephen P Fortmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
8899
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Waitzfelder B, Palaniappan L, Varga A, Frankland T, Li J, Daida Y, et al.
BMC Public Health
. 2023 May;
23(1):885.
PMID: 37189145
Background: Cardiovascular disease (CVD) remains the leading cause of death in the US. CVD incidence is influenced by many demographic, clinical, cultural, and psychosocial factors, including race and ethnicity. Despite...
12.
Floyd J, Walker R, Kuntz J, Shortreed S, Fortmann S, Bayliss E, et al.
J Gen Intern Med
. 2023 Feb;
38(6):1484-1492.
PMID: 36795328
Background: Little is known about whether diabetes increases the risk of COVID-19 infection and whether measures of diabetes severity are related to COVID-19 outcomes. Objective: Investigate diabetes severity measures as...
13.
Nathan D, Lachin J, Bebu I, Burch H, Buse J, Cherrington A, et al.
N Engl J Med
. 2022 Sep;
387(12):1075-1088.
PMID: 36129997
Background: Data are lacking on the comparative effectiveness of commonly used glucose-lowering medications, when added to metformin, with respect to microvascular and cardiovascular disease outcomes in persons with type 2...
14.
Tisminetzky M, Gurwitz J, Tabada G, Reynolds K, Fortmann S, Garcia E, et al.
Am J Med
. 2022 Sep;
135(12):1468-1477.
PMID: 36058306
Background: Current clinical practice guidelines recommend routine kidney function and serum potassium testing within 30 days of initiating angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) therapy. However,...
15.
Smith D, OKeeffe-Rosetti M, Fitzpatrick S, Mayhew M, Firemark A, Gruss I, et al.
Perm J
. 2022 Aug;
26(3):74-82.
PMID: 36038966
BackgroundThe Diabetes Prevention Program (DPP) has been translated into digital formats. We report an economic evaluation of a digital DPP implemented in a large, integrated health care system. MethodsPatients (n...
16.
Fitzpatrick S, Mayhew M, Rawlings A, Smith N, Nyongesa D, Vollmer W, et al.
Clin Diabetes
. 2022 Aug;
40(3):345-353.
PMID: 35983414
The purpose of this natural experiment study was to assess the effectiveness of a 12-month digital Diabetes Prevention Program (DPP) for adults aged 65-75 years with prediabetes and obesity within...
17.
Fitzpatrick S, Mayhew M, Catlin C, Firemark A, Gruss I, Nyongesa D, et al.
Perm J
. 2022 May;
26(1):21-31.
PMID: 35609151
Introduction: Implementation of a Diabetes Prevention Program (DPP) in both in-person and digital health-care settings has been increasing. The purpose of this article is to describe the protocol of a...
18.
Wali B, Frank L, Young D, Meenan R, Saelens B, Dickerson J, et al.
J Transp Health
. 2022 Jan;
24.
PMID: 35096526
Background And Objective: No research to date has causally linked built environment data with health care costs derived from clinically assessed health outcomes within the framework of longitudinal intervention design....
19.
Shortreed S, Gray R, Akosile M, Walker R, Fuller S, Temposky L, et al.
J Racial Ethn Health Disparities
. 2022 Jan;
10(1):149-159.
PMID: 35072944
COVID-19 inequities have been well-documented. We evaluated whether higher rates of severe COVID-19 in racial and ethnic minority groups were driven by higher infection rates by evaluating if disparities remained...
20.
Henriksen L, Schleicher N, Fortmann S
Tob Control
. 2021 Aug;
31(e2):e211-e212.
PMID: 34385403
No abstract available.